Molbio Diagnostics IPO: Can Rapid Growth Trajectory Make it a Long-Term Play for High-Risk Investors?

Molbio Diagnostics IPO: Can Rapid Growth Trajectory Make it a Long-Term Play for High-Risk Investors?​

Molbio Diagnostics, a manufacturer specializing in molecular diagnostic solutions, has announced its Initial Public Offering (IPO). The company is raising capital through a fresh issue of ₹200 crore intended entirely for necessary capital expenditure. Additionally, the IPO includes an offer for sale set to generate ₹740 crore, providing liquidity and funding stability.

Funding Structure and Promoter Stake Details​

The offering carries a significant shift in promoter ownership stake. The current promoter group's stake is 46.6%, which is slated to reduce to 43% following the completion of the IPO. This structure balances capital infusion for growth with divestment via the Offer for Sale mechanism.

Operational Footprint and Market Reach​

Incorporated in 2000, Molbio has established a substantial operational base across India. The company manages six manufacturing facilities domestically. It serves clients in over 90 countries, maintaining strong relationships with government health programmes, international healthcare organizations, hospitals, and diagnostic laboratories.

Molbio's product portfolio includes the 'Truenat' platform, a portable diagnostics system specifically designed for resource-limited settings. This system provides accurate test results within one hour. Furthermore, through subsidiaries and strategic collaborations, the company offers advanced radiology, digital pathology, and breast health screening solutions.

Revenue Drivers and Concentration Risk​

The operational revenue streams show a heavy reliance on diagnostic testing supplies. Nearly 74% of Molbio’s revenue is derived from the sale of test kits. Of those sales, 70% pertain to molecular testing solutions for Tuberculosis. This concentration highlights the specific market focus fueling the company's growth story.

Financial Performance Metrics FY24-FY26​

The financials demonstrate consistent and healthy expansion across key metrics between FY24 and FY26. Revenue from operations expanded by 31.5% annually, reaching ₹1,445.7 crore. Net profit saw a strong annual increase of 40.2%, clocking at ₹164.1 crore over the same period.

During this time frame, Operating Profit before interest, tax, depreciation and amortisation (Ebitda) rose by 33.2% to reach ₹328.2 crore. Correspondingly, the Ebitda margin improved significantly, growing from 22% in FY24 to 22.6% in FY26.

Year-on-Year Growth and Valuation Assessment​

More recently, on a year-on-year basis for FY26, revenue jumped by 41.7%. Ebitda rose 27.9%, while net profit managed an increase of 18.4%. These numbers signal robust momentum in the diagnostic services segment.

Post-IPO valuation demands have been set at a Price-Earnings (P/E) multiple up to 57, based on FY26 post-IPO equity and net profit. While no direct comparable listed peer exists within India, other healthcare diagnostics and medical device companies trade within a P/E range of 54 to 81, suggesting Molbio is valued within the sector's competitive bracket.